Last 12 months
Inside the activity.
3 purchase rows · 2 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 1 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 3 | 1 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 28, 2018 Filed Oct 1, 2018 20:19 UTC |
KILTS JAMES MDirector
|
GrantPhantom Stock Units · Derivative | 780.009 | $44.07 | $34,375.00 |
DisclosureSEC source: 0001225208-18-013900 · doc4.xml · derivative · entry 1 KILTS JAMES M · CIK 0001025094 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,145.444 Underlying: Common Stock · 780.009 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:19 UTC |
NARAYEN SHANTANUDirector
|
GrantPhantom Stock Units · Derivative | 1,063.649 | $44.07 | $46,875.01 |
DisclosureSEC source: 0001225208-18-013901 · doc4.xml · derivative · entry 1 NARAYEN SHANTANU · CIK 0001224154 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 57,533.469 Underlying: Common Stock · 1,063.649 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 20:19 UTC |
SMITH JAMES CDirector
|
GrantPhantom Stock Units · Derivative | 950.193 | $44.07 | $41,875.01 |
DisclosureSEC source: 0001225208-18-013902 · doc4.xml · derivative · entry 1 SMITH JAMES C · CIK 0001611777 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,311.787 Underlying: Common Stock · 950.193 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. F2 · derivative.expiration_date: These units represent deferred director's compensation (including dividend equivalents thereon) that are settled in cash or common stock at the director's election following the reporting person's retirement from the Board of Directors. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 21:31 UTC |
BOURLA ALBERTDirector · Chief Operating Officer
|
GrantPhantom Stock Units SSP · Derivative | 20 | $44.07 | $881.40 |
DisclosureSEC source: 0001225208-18-013937 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,386 Underlying: Common Stock · 20 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 21:31 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $44.07 | $132.21 |
DisclosureSEC source: 0001225208-18-013938 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,581 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 21:31 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 40 | $44.07 | $1,762.80 |
DisclosureSEC source: 0001225208-18-013939 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,030 Underlying: Common Stock · 40 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 28, 2018 Filed Oct 1, 2018 21:31 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 9 | $44.07 | $396.63 |
DisclosureSEC source: 0001225208-18-013940 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,455 Underlying: Common Stock · 9 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 20:08 UTC |
BOURLA ALBERTDirector · Chief Operating Officer
|
GrantPhantom Stock Units SSP · Derivative | 20 | $42.96 | $859.20 |
DisclosureSEC source: 0001225208-18-013461 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,368 Underlying: Common Stock · 20 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 20:08 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 3 | $42.96 | $128.88 |
DisclosureSEC source: 0001225208-18-013462 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,578 Underlying: Common Stock · 3 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 20:08 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 41 | $42.96 | $1,761.36 |
DisclosureSEC source: 0001225208-18-013463 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,992 Underlying: Common Stock · 41 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 14, 2018 Filed Sep 17, 2018 20:08 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 9 | $42.96 | $386.64 |
DisclosureSEC source: 0001225208-18-013464 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,447 Underlying: Common Stock · 9 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 20:08 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 158,662 | $32.23 Strike: $32.23 | $5,113,676.26 |
DisclosureSEC source: 0001225208-18-013465 · doc4.xml · derivative · entry 5 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 158,662 shares Expires 2019-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 20:08 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionStock Appreciation Rights · Derivative | 185,185 | $21.03 Strike: $21.03 | $3,894,440.55 |
DisclosureSEC source: 0001225208-18-013465 · doc4.xml · derivative · entry 4 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 185,185 shares Expires 2019-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 20:08 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 57,211 | $32.23 | $1,843,910.53 |
DisclosureSEC source: 0001225208-18-013465 · doc4.xml · nonDerivative · entry 2 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 234,299 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price) of $41.96) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the fifth anniversary of grant. Read SEC document |
| September 13, 2018 Filed Sep 17, 2018 20:08 UTC |
Dolsten MikaelPresident R&D
|
Exercise / conversionCommon Stock | 124,501 | $21.03 | $2,618,256.03 |
DisclosureSEC source: 0001225208-18-013465 · doc4.xml · nonDerivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 177,088 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents the number of stock units received upon the exercise and conversion of previously granted stock appreciation rights (SARs), calculated by taking the change in our common stock price (20 trading day average ending on the exercise date (Election Price) of $41.96) less the grant price of the SAR plus accumulated dividends from the grant date, times the number of SARs exercised. This value is divided by the Election Price to determine the number of stock units. The stock units and accumulated dividend units will be settled in Pfizer common stock on the SAR original settlement date, the seventh anniversary of grant. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 21:29 UTC |
BOURLA ALBERTDirector · Chief Operating Officer
|
GrantPhantom Stock Units SSP · Derivative | 21 | $41.52 | $871.92 |
DisclosureSEC source: 0001225208-18-013071 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,349 Underlying: Common Stock · 21 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 21:29 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $41.52 | $166.08 |
DisclosureSEC source: 0001225208-18-013072 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,576 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 21:29 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 10 | $41.52 | $415.20 |
DisclosureSEC source: 0001225208-18-013074 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,439 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 31, 2018 Filed Sep 4, 2018 21:29 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 42 | $41.52 | $1,743.84 |
DisclosureSEC source: 0001225208-18-013073 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,953 Underlying: Common Stock · 42 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:21 UTC |
BOURLA ALBERTDirector · Chief Operating Officer
|
GrantPhantom Stock Units SSP · Derivative | 21 | $41.16 | $864.36 |
DisclosureSEC source: 0001225208-18-012702 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,329 Underlying: Common Stock · 21 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:21 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $41.16 | $164.64 |
DisclosureSEC source: 0001225208-18-012703 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,572 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:22 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 43 | $41.16 | $1,769.88 |
DisclosureSEC source: 0001225208-18-012704 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,911 Underlying: Common Stock · 43 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 15, 2018 Filed Aug 17, 2018 01:22 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 10 | $41.16 | $411.60 |
DisclosureSEC source: 0001225208-18-012705 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,430 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 21:04 UTC |
OLSON LAURIE JExecutive Vice President
|
SaleCommon Stock | 10,214 | $41.00 | $418,774.00 |
DisclosureSEC source: 0001225208-18-012551 · doc4.xml · nonDerivative · entry 1 OLSON LAURIE J · CIK 0001553231 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 72,672 Read SEC document |
| August 13, 2018 Filed Aug 14, 2018 21:04 UTC |
Dolsten MikaelPresident R&D
|
OtherPhantom Stock Units · Derivative | 24,504 | $40.81 | $1,000,008.24 |
DisclosureSEC source: 0001225208-18-012552 · doc4.xml · derivative · entry 1 Dolsten Mikael · CIK 0001437590 · President R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,677 Underlying: Common Stock · 24,504 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: The units, held under the Deferred Compensation Plan are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: The units, held under the Deferred Compensation Plan are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 19:19 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 12,442 | $39.50 | $491,459.00 |
DisclosureSEC source: 0001225208-18-012323 · doc4.xml · nonDerivative · entry 6 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,412 Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 19:19 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 6,400 | $39.51 | $252,864.00 |
DisclosureSEC source: 0001225208-18-012323 · doc4.xml · nonDerivative · entry 5 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,854 Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 19:19 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 4,500 | $39.53 | $177,885.00 |
DisclosureSEC source: 0001225208-18-012323 · doc4.xml · nonDerivative · entry 4 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 121,254 Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 19:19 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 2,100 | $39.55 | $83,055.00 |
DisclosureSEC source: 0001225208-18-012323 · doc4.xml · nonDerivative · entry 3 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 125,754 Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 19:19 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 100 | $39.52 | $3,952.00 |
DisclosureSEC source: 0001225208-18-012323 · doc4.xml · nonDerivative · entry 2 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,854 Read SEC document |
| August 03, 2018 Filed Aug 6, 2018 19:19 UTC |
MACKENZIE ALEXANDER RExecutive Vice President
|
SaleCommon Stock | 100 | $39.56 | $3,956.00 |
DisclosureSEC source: 0001225208-18-012323 · doc4.xml · nonDerivative · entry 1 MACKENZIE ALEXANDER R · CIK 0001678459 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,954 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 19:33 UTC |
DAMELIO FRANK AExecutive Vice President
|
SaleCommon Stock | 150,484 | $40.00 | $6,019,360.00 |
DisclosureSEC source: 0001225208-18-012253 · doc4.xml · nonDerivative · entry 1 DAMELIO FRANK A · CIK 0001194004 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 337,391 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 15, 2017. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 19:35 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
SaleCommon Stock | 15,542 | $40.04 | $622,301.68 |
DisclosureSEC source: 0001225208-18-012254 · doc4.xml · nonDerivative · entry 2 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,643 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 19:35 UTC |
LUND-JURGENSEN KIRSTENExecutive Vice President
|
SaleCommon Stock | 5,400 | $40.05 | $216,270.00 |
DisclosureSEC source: 0001225208-18-012254 · doc4.xml · nonDerivative · entry 1 LUND-JURGENSEN KIRSTEN · CIK 0001693493 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,185 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 19:36 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 18,514 | $40.16 | $743,522.24 |
DisclosureSEC source: 0001225208-18-012255 · doc4.xml · nonDerivative · entry 2 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 83,846 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 19:36 UTC |
CANGIALOSI LORETTA VSr. Vice President, Controller
|
SaleCommon Stock | 8,300 | $40.17 | $333,411.00 |
DisclosureSEC source: 0001225208-18-012255 · doc4.xml · nonDerivative · entry 1 CANGIALOSI LORETTA V · CIK 0001174449 · Sr. Vice President, Controller 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 102,360 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 19:38 UTC |
GOETTLER MICHAELGroup President
|
OtherPhantom Stock Units · Derivative | 17,383 | $40.27 | $700,013.41 |
DisclosureSEC source: 0001225208-18-012256 · doc4.xml · derivative · entry 5 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,383 Underlying: Common Stock · 17,383 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: The units, held under the Deferred Compensation Plan are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: The units, held under the Deferred Compensation Plan are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 19:38 UTC |
GOETTLER MICHAELGroup President
|
SaleCommon Stock | 10,958 | $39.69 | $434,923.02 |
DisclosureSEC source: 0001225208-18-012256 · doc4.xml · nonDerivative · entry 4 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,924 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 19:38 UTC |
GOETTLER MICHAELGroup President
|
SaleCommon Stock | 3,340 | $39.71 | $132,631.40 |
DisclosureSEC source: 0001225208-18-012256 · doc4.xml · nonDerivative · entry 3 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,882 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 19:38 UTC |
GOETTLER MICHAELGroup President
|
SaleCommon Stock | 3,300 | $39.70 | $131,010.00 |
DisclosureSEC source: 0001225208-18-012256 · doc4.xml · nonDerivative · entry 2 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,222 Read SEC document |
| August 01, 2018 Filed Aug 3, 2018 19:38 UTC |
GOETTLER MICHAELGroup President
|
SaleCommon Stock | 1,600 | $39.72 | $63,552.00 |
DisclosureSEC source: 0001225208-18-012256 · doc4.xml · nonDerivative · entry 1 GOETTLER MICHAEL · CIK 0001745691 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,522 Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 19:57 UTC |
BOURLA ALBERTDirector · Chief Operating Officer
|
GrantPhantom Stock Units SSP · Derivative | 22 | $39.93 | $878.46 |
DisclosureSEC source: 0001225208-18-012179 · doc4.xml · derivative · entry 1 BOURLA ALBERT · CIK 0001595703 · Director · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,208 Underlying: Common Stock · 22 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 19:57 UTC |
JOHNSON RADY AExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 4 | $39.93 | $159.72 |
DisclosureSEC source: 0001225208-18-012180 · doc4.xml · derivative · entry 1 JOHNSON RADY A · CIK 0001594762 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,532 Underlying: Common Stock · 4 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 19:57 UTC |
ROGERS DAWNExecutive Vice President
|
GrantPhantom Stock Units SSP · Derivative | 44 | $39.93 | $1,756.92 |
DisclosureSEC source: 0001225208-18-012181 · doc4.xml · derivative · entry 1 ROGERS DAWN · CIK 0001742308 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,813 Underlying: Common Stock · 44 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 31, 2018 Filed Aug 2, 2018 19:57 UTC |
YOUNG JOHN DGroup President
|
GrantPhantom Stock Units SSP · Derivative | 10 | $39.93 | $399.30 |
DisclosureSEC source: 0001225208-18-012182 · doc4.xml · derivative · entry 1 YOUNG JOHN D · CIK 0001551792 · Group President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,336 Underlying: Common Stock · 10 shares Expires not disclosed F1 · derivative.exercise_price: Each unit represents one phantom share of common stock. F2 · derivative.exercise_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. F2 · derivative.expiration_date: These units, which were acquired pursuant to the Pfizer Supplemental Savings Plan, are settled in cash following the reporting person's separation from service and may be transferred by the reporting person into an alternative investment account at any time. Read SEC document |
| July 20, 2018 Filed Jul 24, 2018 17:09 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 7,501 | $37.25 | $279,412.25 |
DisclosureSEC source: 0001225208-18-011922 · doc4.xml · nonDerivative · entry 18 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 115,096 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| July 20, 2018 Filed Jul 24, 2018 17:09 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 4,792 | $37.22 | $178,358.24 |
DisclosureSEC source: 0001225208-18-011922 · doc4.xml · nonDerivative · entry 17 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 122,597 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| July 20, 2018 Filed Jul 24, 2018 17:09 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 4,450 | $37.20 | $165,540.00 |
DisclosureSEC source: 0001225208-18-011922 · doc4.xml · nonDerivative · entry 16 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 127,389 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| July 20, 2018 Filed Jul 24, 2018 17:09 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 3,885 | $37.21 | $144,560.85 |
DisclosureSEC source: 0001225208-18-011922 · doc4.xml · nonDerivative · entry 15 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,839 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
| July 20, 2018 Filed Jul 24, 2018 17:09 UTC |
SUSMAN SALLYExecutive Vice President
|
SaleCommon Stock | 3,756 | $37.17 | $139,610.52 |
DisclosureSEC source: 0001225208-18-011922 · doc4.xml · nonDerivative · entry 14 SUSMAN SALLY · CIK 0001263544 · Executive Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 135,724 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 1, 2018. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.